Compare Public Storage (PSA) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Public Storage vs Spyre Therapeutics Inc. Common Stock — how do they compare? Public Storage trades at $290.77 (market cap $53.89B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Public Storage is far larger — about 7.2× Spyre Therapeutics Inc. Common Stock's market cap, and Public Storage pays a 4.16% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Public Storage for 130 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PSA | SYRE | |
|---|---|---|
Market Cap | $53.89B | $7.52B |
Volume | 947,047 | 1,441,031 |
Sector | Real Estate | Health |
52-Week High | $330.47 | $108.92 |
52-Week Low | $258.44 | $22.18 |
Typical Hold Time | 130 Days | 0 Days |
Enterprise Value | $68.16B | $6.52B |
Dividend Yield | 4.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Public Storage (PSA) trades at $288.76, showing minimal daily movement (-0.04%) with neutral technical indicators. The REIT maintains strong fundamentals including a 41.8% net income margin and consistent earnings beats, though valuation metrics appear elevated with a P/E of 27.52. Recent developments include the completion of the Public Storage Canada acquisition and a $400 million Canadian debt offering, positioning for strategic growth.
PSA presents a mixed outlook with analyst consensus pointing to 14% upside to the $328.33 price target, though the majority (64%) recommend Hold. Key risks include REIT sector sensitivity to interest rates and competitive pressures, while the 4.05% dividend yield provides income stability. The stock's premium valuation requires sustained operational execution to justify further gains.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
